Year None2023202220212020201920182017201620152014 Aug 17 Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Aug 10 Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration Aug 9 Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs Aug 3 Regeneron Reports Second Quarter 2023 Financial and Operating Results Aug 1 Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation Jul 29 Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS Jun 29 Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023 Jun 27 Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema Jun 27 FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler May 25 Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page »